<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03562806</url>
  </required_header>
  <id_info>
    <org_study_id>2017-00899</org_study_id>
    <nct_id>NCT03562806</nct_id>
  </id_info>
  <brief_title>MRI 3D UTE Hyper-Cones &amp; ZTE for PET/MR Lung Attenuation Correction &amp; for Lung Diagnostic Imaging</brief_title>
  <official_title>MRI 3D UTE Hyper-Cones &amp; ZTE for PET/MR Lung Attenuation Correction &amp; for Lung Diagnostic Imaging</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Zurich</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Zurich</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      MRI 3D UTE Hyper-Cones &amp; ZTE for PET/MR lung attenuation correction &amp; for lung diagnostic
      imaging
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 23, 2018</start_date>
  <completion_date type="Anticipated">May 23, 2021</completion_date>
  <primary_completion_date type="Anticipated">May 23, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Confirm that lung density map extraction is feasible through Hyper-Cones &amp; ZTE scanning.</measure>
    <time_frame>1 year</time_frame>
    <description>Confirm that lung density map extraction is feasible through Hyper-Cones &amp; ZTE scanning.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Lung Diseases</condition>
  <arm_group>
    <arm_group_label>PET/MR (single arm)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PET and MR sequence acquisition on SIGNA PET/MR device</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>PET/MR image acquisition</intervention_name>
    <description>Acquisition of PET and MR sequences on SIGNA PET/MR device.</description>
    <arm_group_label>PET/MR (single arm)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  informed consent and signature

          -  clinical PET/CT planned and performed at Wagi site in Schlieren

          -  male or female patients

          -  from 18 to 80 years of age.

        Exclusion Criteria:

        - same exclusion criteria as for the clinical PET/CT exam (i.e. pregnant women).

        Additional exclusion criteria:

        - standard exclusion criteria for clinical MRI (evaluated by clinical standard determined
        by MRI questionnaire).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University Hospital Zurich, Department of Nuclear Medicine</name>
      <address>
        <city>Zurich</city>
        <zip>8091</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martin Huellner, MD</last_name>
      <phone>0041442551111</phone>
      <email>martin.huellner@usz.ch</email>
    </contact>
    <investigator>
      <last_name>Martin Huellner, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>May 23, 2018</study_first_submitted>
  <study_first_submitted_qc>June 7, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 20, 2018</study_first_posted>
  <last_update_submitted>May 6, 2020</last_update_submitted>
  <last_update_submitted_qc>May 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

